ReviewiLIVER2022
Perihilar cholangiocarcinoma: a surgeon's perspective.
Review in iLIVER, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- ASO Editorial: Preoperative Systemic Therapy for Perihilar Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Review
- ASO Author Reflections: Reassessing the Value of Additional Proximal Margin Resection for Perihilar Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Prognostic implications of morphological subtypes in a surgical cohort of perihilar cholangiocarcinoma: the overriding impact of nodal status.International journal of clinical oncology · 2025Article
- Cancer surveillance in biliary atresia patients with native liver survival: Standardizing monitoring and follow-up.Pediatric surgery international · 2025Review
- Review
- Is it time to define the scope of safety for robotic resection in perihilar cholangiocarcinoma surgery? A propensity score matching based analysis of a single center experience.Annals of hepato-biliary-pancreatic surgery · 2025Article
- Article
- Improving postoperative survival in cholangiocarcinoma: development of surgical strategies with a screening program in the epidemic region.World journal of surgical oncology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perihilar cholangiocarcinoma (PHC) is defined anatomically as tumors located in the extrahepatic biliary tree proximal to the origin of the cystic duct. However, as the boundary between the extrahepatic and intrahepatic bile ducts is not well defined, PHC potentially includes two types of tumors: one is the extrahepatic type, which arises from the large hilar bile duct, and the other is the intrahepatic type, which has an intrahepatic component with invasion of the hepatic hilus. The new American Joint Commission on Cancer tumor-node-metastasis staging system for PHC was well revised; an important revision is that the Bismuth type IV was removed from T4 stage determinants. Most patients with PHC present with obstructive jaundice, and preoperative biliary drainage is mandatory. Previously, percutaneous transhepatic biliary drainage was used in many centers; however, it has been accepted that endoscopic nasobiliary drainage is the most suitable method for PHC. Recently, inside-stents have also been adopted for biliary drainage, with favorable results. Portal vein embolization is widely performed as presurgical treatment for patients undergoing extended hepatectomy to minimize postoperative liver dysfunction. Surgical resection of PHC is technically demanding and continues to be the most difficult challenge for hepatobiliary surgeons. Because of advances in diagnostic and surgical techniques, surgical outcomes and survival rates after resection have steadily improved. However, survival rates, especially for patients with lymph node metastasis, are unsatisfactory, and establishing a protocol for effective adjuvant chemotherapy is an urgent task. Further synergy of endoscopists, radiologists, oncologists, and surgeons is required to conquer this intractable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.